3 Stocks Dragging The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 34 points (0.2%) at 16,585 as of Friday, May 9, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,493 issues advancing vs. 1,448 declining with 155 unchanged.

The Drugs industry currently sits up 1.0% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include Mylan ( MYL), down 2.3%, AstraZeneca ( AZN), down 2.0%, Shire ( SHPG), down 1.1%, Teva Pharmaceutical Industries ( TEVA), down 0.8% and AbbVie ( ABBV), down 0.8%. Top gainers within the industry include Alexion Pharmaceuticals ( ALXN), up 1.9%, Celgene ( CELG), up 1.6%, Gilead ( GILD), up 1.2%, Merck ( MRK), up 1.1% and Novo Nordisk A/S ( NVO), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Jazz Pharmaceuticals ( JAZZ) is one of the companies pushing the Drugs industry lower today. As of noon trading, Jazz Pharmaceuticals is down $9.54 (-7.1%) to $124.15 on heavy volume. Thus far, 1.8 million shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $120.38-$126.99 after having opened the day at $124.71 as compared to the previous trading day's close of $133.69.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals has a market cap of $8.2 billion and is part of the health care sector. Shares are up 5.6% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Jazz Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Medivation Founder Takes Helm at Axovant, Shares Spike

Trevena, Synergy Lead Biotech Movers

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix